Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Update on prescription extended-release opioids and appropriate patient selection.

Brennan MJ.

J Multidiscip Healthc. 2013 Jul 23;6:265-80. doi: 10.2147/JMDH.S38562. Print 2013.

2.

Tamper-resistant opioid formulations in the treatment of acute pain.

Passik SD.

Adv Ther. 2014 Mar;31(3):264-75. doi: 10.1007/s12325-014-0099-7. Epub 2014 Feb 14. Review.

PMID:
24526323
3.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
4.

Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.

Keast SL, Owora A, Nesser N, Farmer K.

J Manag Care Spec Pharm. 2016 Apr;22(4):347-56. doi: 10.18553/jmcp.2016.22.4.347.

5.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians..

Pain Physician. 2012 Jul;15(3 Suppl):S67-116.

6.

Glial Modulation in Pain States: Translation into Humans.

Horvath RJ, Romero-Sandoval EA, De Leo JA.

In: Kruger L, Light AR, editors. Translational Pain Research: From Mouse to Man. Boca Raton, FL: CRC Press/Taylor & Francis; 2010. Chapter 9.

7.

Chronic pain management issues in the primary care setting and the utility of long-acting opioids.

Zorba Paster R.

Expert Opin Pharmacother. 2010 Aug;11(11):1823-33. doi: 10.1517/14656566.2010.491510. Review.

PMID:
20629606
8.

Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.

Webster LR, Markman J, Cone EJ, Niebler G.

Postgrad Med. 2017 Jan;129(1):102-110. doi: 10.1080/00325481.2017.1268902. Epub 2016 Dec 12. Review.

PMID:
27915497
9.

Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

Bannwarth B.

Drugs. 2012 Sep 10;72(13):1713-23. doi: 10.2165/11635860-000000000-00000. Review.

PMID:
22931520
10.

Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?

Schneider JP, Matthews M, Jamison RN.

CNS Drugs. 2010 Oct;24(10):805-10. doi: 10.2165/11584260-000000000-00000. Review.

PMID:
20839893
11.

Strategies to optimize pain management with opioids while minimizing risk of abuse.

Brennan MJ, Stanos S.

PM R. 2010 Jun;2(6):544-58. doi: 10.1016/j.pmrj.2010.03.011.

PMID:
20630441
12.

The implications of tamper-resistant formulations for opioid rotation.

Pappagallo M, Sokolowska M.

Postgrad Med. 2012 Sep;124(5):101-9. doi: 10.3810/pgm.2012.09.2588.

PMID:
23095430
13.

Clinical strategies for the primary health care professional to minimize prescription opioid abuse.

Gudin JA.

Postgrad Med. 2012 May;124(3):131-8. doi: 10.3810/pgm.2012.05.2556. Review.

PMID:
22691907
14.

Prevention of prescription opioid abuse: the role of the dentist.

Denisco RC, Kenna GA, O'Neil MG, Kulich RJ, Moore PA, Kane WT, Mehta NR, Hersh EV, Katz NP.

J Am Dent Assoc. 2011 Jul;142(7):800-10.

PMID:
21719802
15.

Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?

Lourenço LM, Matthews M, Jamison RN.

Expert Opin Drug Deliv. 2013 Feb;10(2):229-40. doi: 10.1517/17425247.2013.751095. Epub 2012 Dec 20. Review.

PMID:
23252692
16.

Opioid analgesics: does potency matter?

Passik SD, Webster L.

J Opioid Manag. 2014 Jul-Aug;10(4):263-75. doi: 10.5055/jom.2014.0214. Review.

PMID:
25162606
17.

Physicians' beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients.

Turk DC, Dansie EJ, Wilson HD, Moskovitz B, Kim M.

Pain Med. 2014 Apr;15(4):625-36. doi: 10.1111/pme.12352. Epub 2014 Jan 21.

PMID:
24612185
18.

Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse.

Sehgal N, Manchikanti L, Smith HS.

Pain Physician. 2012 Jul;15(3 Suppl):ES67-92. Review.

19.

Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.

Davis MP.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):823-31. doi: 10.1080/17425255.2016.1191469. Epub 2016 Jun 7. Review.

PMID:
27253690
20.

Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.

Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM; Centers for Disease Control and Prevention (CDC)..

MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.

PMID:
26469747

Supplemental Content

Support Center